Reproducible Cost-Effectiveness Models
Can we trust health economic evaluations of new pharmaceuticals? Examining the impact of the researcher's degrees of freedom using a many-analysts approach
Project Overview
Given the large economic and public health consequences of drug reimbursement decisions based on cost-effectiveness evidence, it is essential that the cost-effectiveness evidence provides valid input to decision-makers. Our long-term goal is to develop a framework and guidelines for improving reproducibility and reducing the impact of researcher degrees of freedom in pharmacoeconomic models.
Research Aims
The primary aims of the project are:
- Reproducibility Assessment: To determine to what degree published pharmacoeconomic models of new cancer drugs are reproducible.
- Researcher Degrees of Freedom Analysis: To investigate the impact of researchers' degrees of freedom in the pharmacoeconomic modeling of two novel cancer drugs.
Research Team
- Mikael Svensson Principal Investigator
- Martin Henriksson Co-Investigator • Linköping University
- Naimi Johansson Co-Investigator • Karolinska Institute
- Jonathan Siverskog Co-Investigator • Uppsala University
Presentations & Publications
-
Reproducibility of published model-based cancer drugs cost-effectiveness analyses: a study protocol for a cross-sectional analysis
Mikael Svensson, Jonathan Siverskog, Naimi Johansson and Martin Henriksson
BMJ Open, 2025, 15:e096719